文献速递皮肤肿瘤

二甲双胍使用与皮肤黑色素瘤合并糖尿病患者生存的关联

Association of metformin use and survival in patients with cutaneous melanoma and diabetes.
PubMed 文献 · Br J Dermatol · 2023-01-01

这项基于瑞典黑色素瘤登记的人群队列研究纳入1162例皮肤黑色素瘤合并2型糖尿病患者,评估二甲双胍使用与总生存(OS)和黑色素瘤特异性生存(MSS)的关联。围诊断期使用二甲双胍与全因死亡风险显著降低相关(HR 0.68,95%CI 0.57-0.81),且呈剂量反应模式;未发现与MSS的关联。

要点

  • 围诊断期使用二甲双胍与全因死亡风险显著降低相关(HR 0.68,95%CI 0.57-0.81)。
  • 诊断前后累积使用二甲双胍均与OS改善相关,并呈剂量反应模式。
  • 未发现二甲双胍使用与黑色素瘤特异性生存(MSS)的关联。

核心结论

  • 在皮肤黑色素瘤合并糖尿病患者中,二甲双胍使用与OS改善相关,无论诊断前、诊断后或围诊断期使用,并呈剂量反应模式;但未发现与MSS的关联,作者认为需进一步研究其潜在机制。

研究设计与样本

  • 基于瑞典黑色素瘤登记的人群队列研究,纳入2007年至2014年确诊的原发性浸润性皮肤黑色素瘤成人患者,随访至死亡或2017年12月31日随访结束。
  • 最终队列纳入1162例皮肤黑色素瘤合并2型糖尿病患者,中位随访时间4.1年(四分位距2.4-6.1)。
  • 采用Cox比例风险模型估计粗率和调整后的风险比(HR)及95%置信区间(CI),比较围诊断期使用与不使用二甲双胍,并基于限定日剂量评估剂量反应。

主要发现

  • 围诊断期使用二甲双胍与全因死亡风险显著降低相关(HR 0.68,95%CI 0.57-0.81)。
  • 诊断前每使用6个月二甲双胍与OS改善相关(HR 0.90,95%CI 0.86-0.95)。
  • 诊断后使用0-6个月HR为0.98(95%CI 0.97-0.98),24-30个月HR为0.59(95%CI 0.49-0.70)。
  • 未发现二甲双胍使用与MSS的关联。

关键数值与推荐

  • 围诊断期使用 vs 不使用二甲双胍:全因死亡HR 0.68(95%CI 0.57-0.81)。
  • 诊断前每使用6个月二甲双胍:OS的HR 0.90(95%CI 0.86-0.95)。
  • 诊断后使用0-6个月:OS的HR 0.98(95%CI 0.97-0.98);24-30个月:HR 0.59(95%CI 0.49-0.70)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者认为需进一步研究二甲双胍与生存关联的潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin use has been associated with improved survival in patients with different types of cancer, but research regarding the effect of metformin on cutaneous melanoma (CM) survival is sparse and inconclusive. OBJECTIVES: To investigate the association between metformin use and survival among patients with CM and diabetes. METHODS: All adult patients with a primary invasive CM between 2007 and 2014 were identified in the Swedish Melanoma Registry and followed until death, or end of follow-up on 31 December 2017 in this population-based cohort study. Patients with both CM and type 2 diabetes mellitus were assessed further. Overall survival (OS) and melanoma-specific survival (MSS) were the primary endpoints. Cox proportional hazard models estimating crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were used comparing peridiagnostic use vs. nonuse of metformin. Dose response was evaluated based on defined daily doses. RESULTS: Among a total of 23 507 patients, 1162 patients with CM and type 2 diabetes mellitus were included in the final cohort, with a median follow-up time of 4.1 years (interquartile range 2.4-6.1). Peridiagnostic metformin use was associated with a significantly decreased risk of death by any cause (HR 0.68, 95% CI 0.57-0.81). Cumulative pre- and postdiagnostic metformin use was also associated with improved OS: the HR for prediagnostic use was 0.90 (95% CI 0.86-0.95) for every 6 months of use and the HR for postdiagnostic use ranged from 0.98 (95% CI 0.97-0.98) for 0-6 months to 0.59 (0.49-0.70) for 24-30 months of use. No association was found for metformin use and MSS. CONCLUSIONS: Metformin use was associated with improved OS in patients with CM and diabetes regardless of timing (pre-, post- or peridiagnostic use) and followed a dose-response pattern. However, further research regarding the underlying mechanisms is warranted.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Krakowski I, Häbel H, Nielsen K, et al. Association of metformin use and survival in patients with cutaneous melanoma and diabetes. Br J Dermatol. 2023. PMID: 36689497. doi:10.1093/bjd/ljac003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。